BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7731725)

  • 1. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
    Grubb GR; Yun K; Reeve AE; Eccles MR
    Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome.
    Baird PN; Groves N; Haber DA; Housman DE; Cowell JK
    Oncogene; 1992 Nov; 7(11):2141-9. PubMed ID: 1331933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
    Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
    Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
    Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
    J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the WT1 gene in Wilms' tumour.
    Haber DA; Housman DE
    Cancer Surv; 1992; 12():105-17. PubMed ID: 1322241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The third zinc finger of the WT1 gene is mutated in Wilms' tumour but not in a broad range of other urogenital tumours.
    Quek HH; Chow VT; Tock EP
    Anticancer Res; 1993; 13(5A):1575-80. PubMed ID: 8239537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
    Pritchard-Jones K; Fleming S
    Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
    Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
    Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
    Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
    J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript.
    Algar EM; Kenney MT; Simms LA; Smith SI; Kida Y; Smith PJ
    Hum Mutat; 1995; 5(3):221-7. PubMed ID: 7599632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
    Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
    Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity for chromosome region 11p15 in Wilms' tumours is not related to HRAS gene transforming mutations.
    Baird P; Wadey R; Cowell J
    Oncogene; 1991 Jul; 6(7):1147-9. PubMed ID: 1861864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
    Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
    Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.